Industry Report: Global Traceability and Serialisation Pharma 2014




Download Your Copy

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.

Find out what other serialisation & traceability professionals had to say about key challenges, investment and future priorities

Counterfeit pharmaceuticals pose a significant threat to the viability of the pharmaceutical industry and patient safety. As supply chains become more complex and multidimensional the challenge of tracking a product through the supply chain increases. Pharmaceuticals consistently rank within the top ten categories for counterfeit goods and the risk to products can vary from country to country. In response pharmaceutical manufacturers are investing more in product security initiatives, such as serialisation which involves coding products uniquely at the item level.

With so many solutions being presented, selecting the right technology or strategy can be its own challenge. There is great demand for standardised approaches to counterfeiting and solutions that can be rolled out globally, but this requires unity from pharmaceutical companies, vendors and trade associations.

Download this report, based on our latest survey of serialisation and traceability professionals in the pharmaceutical industry and subsequent telephone interviews with selected individuals, for an insight into:

  • Implementing serialisation: operation challenges, technologies and investment levels
  • Implementing ePedigree in a global company
  • Dealing with the unknown
  • Regulatory compliance with the Drug Supply Chain Security Act and the EU Falsified Medicines Directive

This report has been brought to you in association with the Pharmaceutical Serialisation and Traceability Summit.
[inlinead]

You may also like:

Securing the Pharmaceutical Supply Chain - Interview with Henry Moran, Napp Pharmaceuticals
 

TO READ THE FULL STORY